Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisomycin SCHEMBL18059879 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL8331774 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL2270193 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL59587 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL15033472 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL2270187 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL898674 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL1003579 | 0.99 | SMN1; SMN2 (0.97) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| Anisomycin SCHEMBL6888777 | 0.94 | SMN1; SMN2 (0.89) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 | |
| SCHEMBL18106096 | 0.88 | CYP2D6 (0.78) | SMN1; SMN2CYP2D6ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3226883-B1 | COMPOSITIONS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES | MOR RESEARCH APPLIC LTD (IL) | 2023-11-22 | — | — | EP | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089015-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR LIVESTOCK INFECTIOUS DISEASE CAUSED BY AFRICAN SWINE FEVER VIRUS | 国立研究開発法人農業・食品産業技術総合研究機構 | 2026-04-30 | — | — | WO | disclosed |
| US-12612362-B2 | Anisomycin derivative and use of anisomycin and derivative thereof as GLP-1R agonist | SHANXI MEDICAL UNIVERSITY (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4709874-A1 | MODULATORS OF PROTEIN SECRETION | Sanofi (FR) | 2026-03-18 | — | — | EP | disclosed |
| US-20250313905-A1 | METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | disclosed |
| US-12364717-B2 | Compositions and methods for inhibiting seizures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7666849-B2 | ligands that are designed to specifically kill or inhibit the growth of any target organism | RIB-X PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2053406-A2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | caprotec bioanalytics GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1485707-B1 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | CAPROTEC BIOANALYTICS GMBH (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-1999001150-A1 | NOVEL COMPOSITION FOR TREATING, PREVENTING AND/OR DELAYING ISCHEMIC CELL DEATH | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | SMN1; SMN2 4623/4885CYP2D6 4323/4885ALDH1A1 4360/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | SMN1; SMN2 294/4885CYP2D6 630/4885ALDH1A1 1382/4885 |
| US-12612362-B2 | Anisomycin derivative and use of anisomycin and derivative thereof as GLP-1R agonist | GLP1R, GIPR, GPR119 | SMN1; SMN2 1606/4885CYP2D6 2161/4885ALDH1A1 1548/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | SMN1; SMN2 217/4885CYP2D6 4614/4885ALDH1A1 2370/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | SMN1; SMN2 3130/4885CYP2D6 4202/4885ALDH1A1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.